Highlights Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Market Closed - Japan Exchange Other stock markets 11:30:00 08/05/2024 am IST			5-day change	1st Jan Change
6,384 ^JPY	-1.24%		-5.31%	+20.70%

30/04	Otsuka Holdings' Attributable Profit Jumps 26% in Q1	MT
29/04	Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Otsuka Holdings' Attributable Profit Jumps 26% in Q1	30/04	MT
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter of 2024	30/04	CI
Otsuka Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	30/04	CI
Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation	29/04	MT
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04	MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	29/03	MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03	MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18/03	MT
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	26/02	DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16/02	MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	16/02	CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	16/02	CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	14/02	CI
Otsuka Holdings Lowers 2023 Profit Outlook	13/02	MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	13/02	RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023	13/02	CI
Final dividend	28/12	FA
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema	19/12	MT
Otsuka Unit Buys New York-Based Provider of Women Health Products	05/12	MT
US FDA approves Medtronic's blood pressure treatment device for use	18/11	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Highlights

Filters